Cingulate Inc (CING) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cingulate Inc (CING) has a cash flow conversion efficiency ratio of -1.434x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.60 Million) by net assets ($2.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CING net asset quality index to measure how much of total assets are equity-financed.
Cingulate Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Cingulate Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Cingulate Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Cingulate Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cingulate Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
As Commercial Industrial Company of Computers and Toys S.A.
AT:ASCO
|
0.028x |
|
Smart Digital Group Limited Ordinary Shares
NASDAQ:SDM
|
N/A |
|
Mcleod Russel India Limited
NSE:MCLEODRUSS
|
-0.521x |
|
Ilyda SA
AT:ILYDA
|
0.032x |
|
Computacenter PLC
LSE:CCC
|
-0.097x |
|
Meta Biomed Co. Ltd
KQ:059210
|
0.009x |
|
Mastermyne Group Ltd
AU:MYE
|
0.071x |
|
Mesa Air Group Inc
NASDAQ:MESA
|
0.054x |
Annual Cash Flow Conversion Efficiency for Cingulate Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Cingulate Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Cingulate Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.51 Million | $-17.25 Million | -6.874x | -177.73% |
| 2024-12-31 | $7.46 Million | $-18.45 Million | -2.475x | -213.08% |
| 2023-12-31 | $-6.87 Million | $-15.03 Million | 2.189x | +153.49% |
| 2022-12-31 | $3.88 Million | $-15.88 Million | -4.091x | -717.41% |
| 2021-12-31 | $20.84 Million | $-10.43 Million | -0.501x | +90.50% |
| 2020-12-31 | $1.29 Million | $-6.81 Million | -5.270x | +65.95% |
| 2019-12-31 | $615.88K | $-9.53 Million | -15.478x | -- |
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It … Read more